These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18598995)

  • 1. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
    Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
    Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
    Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious adverse events with infliximab: analysis of spontaneously reported adverse events.
    Hansen RA; Gartlehner G; Powell GE; Sandler RS
    Clin Gastroenterol Hepatol; 2007 Jun; 5(6):729-35. PubMed ID: 17481964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with biologic therapies and the risk of cancer in patients with IBD.
    Biancone L; Calabrese E; Petruzziello C; Pallone F
    Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inflammatory bowel diseases].
    Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
    Rev Med Suisse; 2005 Jan; 1(3):218-20, 223-7. PubMed ID: 15770816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab use in children and adolescents with inflammatory bowel disease.
    de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
    Lee LY; Sanderson JD; Irving PM
    Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1078-85. PubMed ID: 22647738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab in ulcerative colitis.
    Aberra FN; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
    Theis VS; Rhodes JM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
    Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.